Our logistic regression model found an increased likelihood of receiving low-value PSA tests for prostate cancer screening in populations who were younger, Hispanic, or Asian; owned a home; had fewer baseline comorbidities; had higher baseline health utilization; and reported lower baseline health care costs (Table 2). This evidence concerns the gene KLK3 and prostate carcinoma.